Switch to:
More From Other Websites
U.S. FDA approves AbbVie hepatitis C drug, costs $83,319 for 12 weeks Dec 19 2014
AbbVie says newly approved hepatitis C treatment costs $83,319 Dec 19 2014
[$$] FDA Backs AbbVie's Hepatitis Treatment Dec 19 2014
5:47 pm AbbVie confirms FDA approval of Viekira Pak for the treatment of chronic genotype 1... Dec 19 2014
AbbVie's Hepatitis-C Treatment Approved, Bad news for Gilead? Dec 19 2014
Abbvie's Hep C Regimen Approved, Marketing Battle With Gilead Up Next Dec 19 2014
FDA approves AbbVie’s hepatitis treatment Dec 19 2014
U.S. FDA approves AbbVie all-oral hepatitis C treatment Dec 19 2014
AbbVie: Here's How It Could Differentiate Itself From Gilead Dec 18 2014
AbbVie Pins Hopes on Hepatitis C Treatment Dec 18 2014
Shire considering bid for NPS Pharmaceuticals - Bloomberg Dec 17 2014
Shire considering bid for NPS Pharmaceuticals - Bloomberg Dec 17 2014
Shire Said to Weigh Offer for NPS as It Revisits Deals Dec 17 2014
Viekirax/Exviera vs. Harvoni: Clash of the Hep C Drugs 2015 Dec 16 2014
Will AbbVie Undercut Gilead on Hepatitis C? Dec 11 2014
Analysts' Actions: AbbVie, Ariad, Lilly, Prologis, Toll Brothers Dec 11 2014
Gilead Is Growing Fast And Its Stock Is Cheap Dec 11 2014
Walgreens CEO announces plans to step down Dec 10 2014
AbbVie Reveals Phase II Data on Blood Cancer Drug at ASH (Revised) Dec 10 2014
Gilead Sciences: Still Waiting on AbbVie Dec 09 2014


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK